Aromatase Inhibitors in Breast Cancer

This publication has 30 references indexed in Scilit:

• Extended Adjuvant Therapy With Anastrozole Among Postmenopausal Breast Cancer Patients: Results From the Randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a
  JNCI Journal of the National Cancer Institute, 2007
• Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective
  Breast Cancer Research and Treatment, 2007
• Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial
  Breast Cancer Research and Treatment, 2007
• Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial
  The Lancet, 2005
• Benefit and projected cost‐effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early‐stage estrogen receptor–positive breast cancer
  Cancer, 2004
• A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
  New England Journal of Medicine, 2004
• A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
  New England Journal of Medicine, 2003
• A Stochastic Economic Evaluation of Letrozole versus Tamoxifen as a First-Line Hormonal Therapy
  PharmacoEconomics, 2003
• Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer
  Cancer Treatment Reviews, 2000
• Economic Evaluation of Letrozole in the Treatment of Advanced Breast Cancer in Postmenopausal Women in Canada
  Value in Health, 2000